|
|
Vaccine Detail
|
Alpha Fetoprotein Adenoviral Vector Vaccine |
| Vaccine Information |
- Vaccine Name: Alpha Fetoprotein Adenoviral Vector Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007235
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- AFP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Priming mice with plasmids encoding AFP and GM-CSF and boosting with adenovirus encoding AFP elicits robust T-cell responses to defined AFP class I peptide epitopes and strong protective immunity (Meng et al., 2001).
- Description: A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05) (NCIT_C48372).
This vaccine has been used in hepatocellular carcinoma.(He et al., 2014)
|
| Host Response |
|
|
| References |
He et al., 2014: He Y, Hong Y, Mizejewski GJ. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy. 2014; 6(6); 725-736. [PubMed: 25041030].
Meng et al., 2001: Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer research. 2001; 61(24); 8782-8786. [PubMed: 11751399].
NCIT_C48372: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48372]
|
|
